Industry Strength Score
66/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ORAMED PHARMACEUTICALS INC (ORMP) Stock Price & Overview
NASDAQ:ORMP • US68403P2039
Current stock price
3.98 USD
+0.1 (+2.58%)
Last:
The current stock price of ORMP is 3.98 USD. Today ORMP is up by 2.58%. In the past month the price increased by 14.45%. In the past year, price increased by 67.24%.
ORMP Key Statistics
52-Week Range1.975 - 4.2199
Current ORMP stock price positioned within its 52-week range.
1-Month Range3.3064 - 4.2199
Current ORMP stock price positioned within its 1-month range.
- Market Cap
- 160.991M
- P/E
- 2.69
- Fwd P/E
- N/A
- EPS (TTM)
- 1.48
- Dividend Yield
- 6.49%
ORMP Stock Performance
Today
+2.58%
1 Week
+1.04%
1 Month
+14.45%
3 Months
+15.13%
Longer-term
6 Months +62.34%
1 Year +67.24%
2 Years +67.24%
3 Years +70.93%
5 Years -63.60%
10 Years -55.25%
ORMP Stock Chart
ORMP Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ORMP. When comparing the yearly performance of all stocks, ORMP is one of the better performing stocks in the market, outperforming 87.78% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ORMP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ORMP. ORMP has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ORMP Earnings
Next Earnings DateAug 12, 2026
Last Earnings DateMar 26, 2026
PeriodQ4 / 2025
EPS Reported$0.24
Revenue Reported
EPS Surprise %
Revenue Surprise %
ORMP Forecast & Estimates
6 analysts have analysed ORMP and the average price target is 6.38 USD. This implies a price increase of 60.18% is expected in the next year compared to the current price of 3.98.
For the next year, analysts expect an EPS growth of -186.56% and a revenue growth -100% for ORMP
Analysts
Analysts43.33
Price Target6.38 (60.3%)
EPS Next Y-186.56%
Revenue Next Year-100%
ORMP Index Membership
ORMP is currently included in the following stock indexes tracked on ChartMill.
ORMP Financial Highlights
Over the last trailing twelve months ORMP reported a non-GAAP Earnings per Share(EPS) of 1.48. The EPS increased by 924.83% compared to the year before.
Income Statements
Revenue(TTM)2.00M
Net Income(TTM)64.05M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3202.5% | ||
| ROA | 27.74% | ||
| ROE | 32.07% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%197.65%
Sales Q2Q%N/A
EPS 1Y (TTM)924.83%
Revenue 1Y (TTM)N/A
ORMP Ownership
Ownership
Inst Owners27.4%
Shares40.45M
Float32.91M
Ins Owners15.21%
Short Float %1.75%
Short Ratio4.24
ORMP Industry Overview
ORMP operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
34%
Outperformed 34% of sub-industries
3 Month Rank
52%
Outperformed 52% of sub-industries
6 Month Rank
39%
Outperformed 39% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 4.4%
- New Lows
- 3.7%
- Average ROE
- 51.3%
- Average Profit Margin
- 27.9%
- Average Operating Margin
- 37.7%
- Average P/E
- 25.7
- Average Fwd P/E
- 17.9
- Average Debt/Equity
- 1.2
ORMP Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.64 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 18.01 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.5 | 269.662B | ||
| PFE | PFIZER INC | 8.83 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.51 | 123.709B | ||
| ZTS | ZOETIS INC | 16.16 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.59 | 28.899B | ||
| VTRS | VIATRIS INC | 5.97 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.38 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 34.46 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ORMP
Company Profile
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Company Info
IPO: 2002-04-01
ORAMED PHARMACEUTICALS INC
1185 Avenue Of The Americas, 3Rd Floor
New York City NEW YORK 10036 US
CEO: Nadav Kidron
Employees: 4
Phone: 16468441164
ORAMED PHARMACEUTICALS INC / ORMP FAQ
What does ORMP do?
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
What is the current price of ORMP stock?
The current stock price of ORMP is 3.98 USD. The price increased by 2.58% in the last trading session.
What is the dividend status of ORAMED PHARMACEUTICALS INC?
ORAMED PHARMACEUTICALS INC (ORMP) has a dividend yield of 6.49%. The yearly dividend amount is currently 0.
What is the ChartMill rating of ORAMED PHARMACEUTICALS INC stock?
ORMP has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How many employees does ORAMED PHARMACEUTICALS INC have?
ORAMED PHARMACEUTICALS INC (ORMP) currently has 4 employees.
What is the market capitalization of ORMP stock?
ORAMED PHARMACEUTICALS INC (ORMP) has a market capitalization of 160.99M USD. This makes ORMP a Micro Cap stock.
Who owns ORAMED PHARMACEUTICALS INC?
You can find the ownership structure of ORAMED PHARMACEUTICALS INC (ORMP) on the Ownership tab.